Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer

Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer

Background: Chemotherapy-induced peripheral neuropathy is commonly observed in patients treated with nanoparticle albumin–bound paclitaxel (nab-PTX). We conducted a multicenter randomized controlled study to evaluate the optimal dose of nab-PTX. Methods: We compared three different doses of q3w nab-...

Full description

Bibliographic Details
Main Authors: Junji Tsurutani, Fumikata Hara, Masahiro Kitada, Masato Takahashi, Yuichiro Kikawa, Hiroaki Kato, Eiko Sakata, Yoichi Naito, Yoshie Hasegawa, Tsuyoshi Saito, Tsutomu Iwasa, Naruto Taira, Tsutomu Takashima, Kosuke Kashiwabara, Tomohiko Aihara, Hirofumi Mukai
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:Breast
Subjects:
Nab-paclitaxel
Nanoparticle albumin–bound paclitaxel
Metastatic breast cancer
Solvent-base paclitaxel
Chemotherapy-induced peripheral neuropathy
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977620302319

Internet

http://www.sciencedirect.com/science/article/pii/S0960977620302319

Similar Items